Heartseed, Inc. (219A) AI Stock Analysis

• Market Cap: ¥46.36B
• Dividend Yield: N/A
• Average Volume (3M): 738.74K
• Price to Earnings (P/E): 76.0
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: JP
• Employees: 39
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 15.44
• Shares Outstanding: 22,858,200
• 10 Day Avg. Volume: 469,170
• 30 Day Avg. Volume: 738,736
• PEG Ratio: -0.38
• Price to Book (P/B): 5.16
• Price to Sales (P/S): 12.91
• P/FCF Ratio: 37.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -130.4
• Revenue Forecast (FY): N/A

• Rating: 63 Neutral
• Price Target: ¥2,099.00 ▲(16.35% Upside)
• Action: Reiterated Date: 02/19/26
• Date: Action: Reiterated 02/19/26

The score is driven primarily by the FY2025 financial turnaround (profitability and positive free cash flow) and a strong, low-leverage balance sheet. This is tempered by the prior multi-year loss/cash-burn history and an expensive valuation (high P/E), while technicals are neutral-to-modestly supportive but still below the 200-day trend.

Positive Factors

Return to positive cash flow

FY2025’s shift to sustained positive operating and free cash flow indicates the company can internally fund operations and reinvest in R&D and commercialization without near‑term capital raises. Predictable cash generation materially lowers funding risk and supports long‑term program continuity.

Very low leverage balance sheet

Extremely low leverage provides durable financial flexibility, reducing insolvency risk and enabling the firm to support lengthy clinical programs or frontload commercial investments. A conservative balance sheet is a lasting buffer through biotech funding cycles and operational setbacks.

Revenue and margin expansion

The sharp FY2025 revenue increase alongside ~23% EBIT and ~20% net margins demonstrates the business can scale revenue with healthy unit economics. If persistent, this improved margin profile enhances capital efficiency, supports R&D funding, and signals a more sustainable commercial model.

Negative Factors

Prior multi-year losses and cash burn

A multi‑year history of steep losses and cash burn means FY2025’s improvement must be sustained to be durable. The company remains vulnerable to reversals that could force dilution or debt financing; past funding dependence signals structural risk until multi‑year cash generation is proven.

Inconsistent gross profit reporting

Irregular gross profit disclosure and an anomalous zero gross profit reading in FY2025 weaken confidence in reported margin trends. This opacity complicates forecasting and makes it harder to assess whether profitability is driven by structural operating improvement or accounting/one‑time factors.

Earnings volatility & execution risk

The swing from multi‑year losses to a single profitable year reveals meaningful execution and outcome risk. For a medical/pharma company, continued commercialization, clinical outcomes, and operational scaling must succeed repeatedly for gains to persist, making future earnings uncertain.

Heartseed, Inc. Business Overview & Revenue Model

Company Description

Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Heartseed, Inc. generates revenue primarily through the development and commercialization of its therapeutic products. The company’s revenue model includes several key streams: licensing agreements with pharmaceutical companies, grant funding for research and development, and potential milestone payments associated with clinical trial progress. Additionally, partnerships with academic institutions and healthcare organizations enhance its research capabilities and may provide funding opportunities. As the company advances its products through clinical trials and approaches regulatory approval, it stands to gain substantial financial returns from product sales and royalties.

Heartseed, Inc. Financial Statement Overview

Summary

FY2025 shows a clear inflection with strong revenue growth, a return to solid profitability, and positive operating/free cash flow, supported by a very low-debt balance sheet. The main offset is high volatility: FY2022–FY2024 featured large losses and cash burn, and inconsistent gross profit reporting reduces confidence in margin comparability.

Income Statement

The company shows a sharp operating turnaround in FY2025: revenue jumped to ~3.0B with solid profitability (about 20% net margin and ~23% EBIT margin) versus steep losses in FY2022–FY2024. Revenue growth also accelerated meaningfully in FY2025 after modest/negative growth earlier. Offsetting this strength, the prior multi-year loss profile highlights earnings volatility and execution risk, and gross profit reporting is inconsistent across years (FY2025 shows zero gross profit), which reduces confidence in comparability of margins.

Balance Sheet

The balance sheet is conservatively structured with extremely low leverage (debt-to-equity near zero across all years) and a large equity base relative to assets, providing strong financial flexibility. Return on equity improved to positive in FY2025 after negative returns in FY2022–FY2024, signaling improving capital efficiency. The main weakness is that the multi-year loss period suggests equity value could be sensitive to future profitability, but current leverage risk appears minimal.

Cash Flow

Cash generation improved dramatically in FY2025 with positive operating cash flow (~1.1B) and positive free cash flow (~1.05B), and free cash flow closely tracked reported profits (free cash flow roughly equal to net income). However, FY2022–FY2024 showed materially negative operating and free cash flow, indicating a history of cash burn and higher funding dependence during downturn periods; the sustainability of FY2025’s cash performance remains a key watch item.

Breakdown	Oct 2025	Oct 2024	Oct 2023	Oct 2022
Income Statement
Total Revenue	3.03B	873.61M	344.73M	499.06M
Gross Profit	0.00	873.61M	344.73M	499.06M
EBITDA	735.84M	-776.36M	-1.45B	-1.41B
Net Income	592.50M	-812.73M	-1.47B	-1.41B
Balance Sheet
Total Assets	8.14B	7.07B	5.72B	4.94B
Cash, Cash Equivalents and Short-Term Investments	7.34B	5.30B	4.59B	3.99B
Total Debt	890.00K	5.39M	11.58M	30.98M
Total Liabilities	571.35M	444.35M	450.19M	208.45M
Stockholders Equity	7.57B	6.62B	5.27B	4.73B
Cash Flow
Free Cash Flow	1.05B	-1.41B	-1.13B	-1.92B
Operating Cash Flow	1.08B	-1.34B	-797.93M	-1.92B
Investing Cash Flow	72.64M	-67.13M	-425.69M	-994.00K
Financing Cash Flow	375.76M	2.12B	1.85B	-22.16M

Heartseed, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1804.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:219A, the sentiment is Positive. The current price of 1804 is below the 20-day moving average (MA) of 1925.05, below the 50-day MA of 1916.64, and below the 200-day MA of 2518.97, indicating a neutral trend. The MACD of 4.03 indicates Negative momentum. The RSI at 58.95 is Neutral, neither overbought nor oversold. The STOCH value of 35.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:219A.

Heartseed, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4595	81 Outperform	¥36.69B	10.71	―	6.29%	-12.03%	-19.61%
219A	63 Neutral	¥46.36B	76.00	―	―	―	―
4552	58 Neutral	¥85.88B	-34.65	―	2.71%	7.15%	-454.41%
7774	54 Neutral	¥32.33B	-70.05	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4894	45 Neutral	¥66.68B	-86.57	―	―	1772.85%	16.16%
4599	43 Neutral	¥19.24B	-10.06	―	―	―	11.34%

Heartseed, Inc. Corporate Events

Heartseed Issues Cautionary Notice Alongside FY2025 Financial Results

Heartseed Inc. has released an informational document presenting its financial results for the fiscal year ended December 31, 2025, emphasizing that the materials are for informational purposes only and may be subject to change without notice. The company underscores that it does not guarantee the accuracy or completeness of the data, restricts reproduction or redistribution of the materials, and clarifies that the document does not constitute an offer to sell or solicit the purchase of its securities.

The release also highlights that any discussion of future business results constitutes forward-looking statements based on current conditions and management judgment, which are inherently subject to risks and uncertainties that may cause actual outcomes to differ materially. Heartseed further notes that some information is derived from third-party public sources without independent verification, and advises stakeholders to refer to its official disclosure channels for more comprehensive and authoritative information on its business and securities.

The most recent analyst rating on (JP:219A) stock is a Sell with a Yen1469.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.

Heartseed Swings to Profit in 2025 but Signals Return to Loss on Higher 2026 Investment

Heartseed Inc. reported non-consolidated net sales of ¥3,026 million for the 14‑month fiscal period ended December 31, 2025, a sharp increase from the prior year’s ¥873 million, turning to an operating profit of ¥272 million and net profit of ¥190 million. The company strengthened its financial position with total assets rising to ¥7,675 million, equity ratio at 93.7%, and cash and cash equivalents at ¥6,836 million, supported by positive operating and financing cash flows.

Despite the improved 2025 results, Heartseed guided for a challenging 2026, forecasting net sales of ¥451 million and a return to a net loss of ¥2,158 million as it steps up investment in its business. The company maintained a no‑dividend policy for 2025 and projected 2026, signaling continued prioritization of R&D and growth spending over shareholder returns in the near term, which may weigh on earnings but underscores its long‑term development focus.

The most recent analyst rating on (JP:219A) stock is a Sell with a Yen1469.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.

Heartseed Inc. Revises Financial Forecast with Positive Outlook

Heartseed Inc. announced a revision of its full-year financial forecast for the fiscal year ending December 31, 2025, due to lower-than-expected research and development expenses. The revised forecast indicates significant improvements in operating, ordinary, and net profits, suggesting a positive financial outlook for the company.

The most recent analyst rating on (JP:219A) stock is a Hold with a Yen1361.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.

Heartseed Inc. Reports Strong Financial Recovery

Heartseed Inc. reported significant financial improvement for the twelve months ending October 31, 2025, with net sales rising to 3,026 million yen from 873 million yen the previous year. The company achieved a net profit of 592 million yen compared to a loss in the prior year, indicating a strong recovery and positive outlook for stakeholders.

The most recent analyst rating on (JP:219A) stock is a Hold with a Yen1361.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.